|
|
Upfront Briefing
Biotech heads into Monday with the tape still cooperative and the newsflow doing its part. J&J grabbed the loudest headline with a Phase 3 Talvey combo win in earlier-line myeloma, Sanofi expanded Tzield into recently diagnosed stage 3 type 1 diabetes, and Lilly added another hematology proof point with Jaypirca in CLL/SLL.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,431.5 |
0.5% |
8.4% |
| Nasdaq 100 |
29,635.9 |
0.6% |
17.6% |
| Russell 2000 |
2,944.0 |
0.8% |
17.4% |
| Healthcare (XLV) |
153.8 |
(0.2%) |
(1.1%) |
| Biotech (XBI) |
133.8 |
0.8% |
10.1% |
| Nasdaq Biotech (NBI) |
5,938.5 |
0.3% |
4.1% |
| Clinical Trials (BBC) |
43.0 |
1.9% |
14.4% |
|
- EHA wrapped in Stockholm (Jun 11–14) and the haem readouts did the lifting — J&J's Talvey MonumenTAL-3 myeloma combo and Lilly's BRUIN CLL-322 Jaypirca data led a tape where XBI added 0.8% and the clinical-stage BBC popped 1.9%, outrunning defensive healthcare as XLV slipped 0.2%.
- The broad tape rode risk-on into the weekend: SpaceX's record Nasdaq debut (+19% off its $135 IPO price) and building U.S.–Iran peace optimism pulled capital into small caps, lifting the Russell 2000 0.8% while crude eased ~2% to near $85.
- Market data: U.S. cash close Friday, 12 June 2026.
The Big 3
|
1
|
J&J posts Phase 3 Talvey combo win in earlier-line myeloma
|
- TALVEY plus daratumumab, with or without pomalidomide, cut progression-or-death risk by up to 72.0% in Phase 3 MonumenTAL-3, with 24-month PFS up to 81.3% versus 51.2% for standard care.
- Why it matters: Moving TALVEY up into earlier relapsed/refractory myeloma widens its addressable pool and tightens J&J's grip on the franchise economics. The up-to-72% progression-or-death reduction and 81.3% vs 51.2% 24-month PFS reset the efficacy bar for bispecific-based combinations — and lean on rivals to show comparable depth from a regimen built on the daratumumab backbone already standard in most myeloma clinics.
- Source: Fierce Pharma
- More: PR
|
|
2
|
Sanofi wins US approval for Tzield in stage 3 type 1 diabetes
|
- Tzield won FDA accelerated approval in newly diagnosed stage 3 type 1 diabetes for children 8–17 — the first disease-modifying therapy cleared in this post-diagnosis setting — on the strength of the Phase 3 PROTECT trial (n=328).
- Why it matters: Tzield already owned stage 2 prevention down to age one; this pushes it across the diagnosis line into newly diagnosed stage 3, where the job is preserving residual beta-cell function rather than delaying onset. The catch is the pathway — it's an accelerated approval resting on PROTECT's C-peptide data, so the label hangs on the confirmatory BETA-PRESERVE Phase 3 reading out clean. The other gating factor is real-world, not clinical: uptake needs autoantibody screening to flag patients before too much beta-cell function is already gone.
- Source: PR
- More: Medscape
|
| 3 | Lilly Jaypirca cuts progression risk in Phase 3 CLL/SLL |
-
Jaypirca cut disease progression or death risk by 45% when added to a venetoclax time-limited regimen in previously treated CLL/SLL in Phase 3 BRUIN CLL-322.
- Why it matters: BRUIN CLL-322 pushes Jaypirca toward an earlier, larger relapsed CLL/SLL setting and strengthens Lilly's case that a non-covalent BTK inhibitor can anchor combination regimens rather than serve only as salvage therapy. For investors, the 45% PFS-risk reduction raises the odds of label expansion and increases pressure on competing BTK- and venetoclax-based sequencing strategies.
- Source: PR
|
Everything Else that broke
- Novartis's del-brax hit its primary biomarker endpoint in a Phase 1/2 FSHD cohort (n=51), teeing up FDA accelerated-approval talks for the lead asset from its $12B Avidity buyout. — Fierce Biotech
- Intellia posted additional positive Phase 3 HAELO data for lonvo-z in hereditary angioedema. — PR
- Merck won adjuvant kidney cancer approval for Welireg plus Keytruda after surgery. — FDA
- Belite finished the rolling NDA for once-daily tinlarebant in Stargardt disease type 1. — PR
- Menarini's Phase 3 SENTRY hit a co-primary endpoint for selinexor plus ruxolitinib in myelofibrosis. — PR
- Legend showed clinical proof of concept for in vivo CAR-T candidate LB2501 in B-cell NHL. — PR
- Ascendis reported Phase 3 TransCon PTH data through week 182 in hypoparathyroidism. — PR
- Roche won FDA clearance for the first PTEN protein companion diagnostic in prostate cancer. — PR
- CMS proposed a permanent framework for Medicare drug price negotiations under the IRA. — Fierce Pharma
- WuXi AppTec sued the Pentagon over its Chinese military list designation. — Endpoints
- Amgen defended Tavneos as FDA reviews evidence on the drug's continued market presence. — Endpoints
- Upstream Bio showed roughly 80% achieved clinically meaningful polyp-score improvement with verekitug in Phase 2 CRSwNP. — PR
- Mineralys presented lorundrostat biomarker data tied to lower heart-failure risk in uncontrolled hypertension. — PR
- Lundbeck highlighted new Phase II asedebart data in Cushing's disease at ENDO 2026. — PR
- Lilly shared first clinical data for AJ1-11095, a type II JAK2 inhibitor, in myelofibrosis. — Fierce Biotech
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
No notable M&A / BD&L since the last edition.
VC / Private Financings
- Neion Bio closed an oversubscribed $23M Series A led by Caffeinated Capital, joined by Basis Set Ventures, to scale its egg-based ("Raptor") biologics-manufacturing platform and expand a biosimilars-led pipeline. — Endpoints
- HMNC Brain Health raised a $50M Series B led by Medice to advance two depression programs. — Company
IPOs / Follow-Ons
- Parabilis completed its upsized IPO, with gross proceeds of ~$770M after full overallotment exercise. — BioCentury
- SL Bio closed its business combination with Horizon Space Acquisition II and listed on Nasdaq. — PR
Academic Corner - NEJM published the full Phase 3 HAELO results for Intellia's lonvo-z, the first pivotal dataset for an in vivo CRISPR therapy — a one-time edit of KLKB1 to lower kallikrein in hereditary angioedema. — NEJM
|
That's the tape — EHA's done printing, the IPO window's wide open, and biotech's still bid. — BioBucks Team
|
|
|
